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Abstract
Background: Previous studies have assessed the validity of the observational study design by
comparing results of studies using this design to results from randomized controlled trials. The
present study examined design features of observational studies that could have influenced these
comparisons.
Methods: To find at least 4 observational studies that evaluated the same treatment, we reviewed
meta-analyses comparing observational studies and randomized controlled trials for the assessment
of medical treatments. Details critical for interpretation of these studies were abstracted and
analyzed qualitatively.
Results: Individual articles reviewed included 61 observational studies that assessed 10 treatment
comparisons evaluated in two studies comparing randomized controlled trials and observational
studies. The majority of studies did not report the following information: details of primary and
ancillary treatments, outcome definitions, length of follow-up, inclusion/exclusion criteria, patient
characteristics relevant to prognosis or treatment response, or assessment of possible
confounding. When information was reported, variations in treatment specifics, outcome definition
or confounding were identified as possible causes of differences between observational studies and
randomized controlled trials, and of heterogeneity in observational studies.
Conclusion: Reporting of observational studies of medical treatments was often inadequate to
compare study designs or allow other meaningful interpretation of results. All observational studies
should report details of treatment, outcome assessment, patient characteristics, and confounding
assessment.
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Introduction
As compared to randomized controlled trials of medical
interventions, observational studies (OSs) are likely to be
more timely, less expensive, and include patients more
representative of usual clinical practice. In addition, OSs
avoid ethical issues caused by compromising the patients'
or physicians' therapeutic choices. However, their validity
is vigorously debated [1,2]. Concerns about validity were
heightened by a well-publicized randomized controlled
trial (RCT) that found an increased risk of heart disease for
women on hormone replacement therapy [3]. This study
contradicted results from several previous high profile
OSs [4-6].
It is possible that OSs are particularly ill-suited to evaluate
hormone replacement therapy. The choice of this therapy
is greatly influenced by patient ideas about youth and
femininity, which may be highly confounded by unmeas-
ured factors affecting health. Not all OSs found a
decreased risk, however [7,8], and one study found evi-
dence that adjusting results for socioeconomic status
yielded similar results to randomized controlled trials [9].
Other factors contributing to differences between the
types of studies may include design features that do not
necessarily influence validity, such as the older age of
women in the randomized trials.
Even if OSs of hormone replacement therapy are shown to
be invalid, the observational study design may still have a
role in the assessment of other medical treatments. For
example, these studies may give good results for evalua-
tion of a surgical procedure that is determined primarily
by physician familiarity with a specific treatment or by
treatment availability. Support for the validity of some
OSs comes from reviews that found that observational
and randomized studies often give similar results [10-13].
The present study investigated the comparisons of OSs
and RCTs in more depth. In addition to the comparisons,
we examined design features of the OSs that could have
influenced these comparisons. In the process of this exam-
ination, we assessed how well OSs of medical treatments
were reported.
Materials and methods
Each of the reviewed studies compared outcomes of a
given medical treatment to outcomes of a comparison
group, which was most often standard therapy. Studies
were selected from articles that compared results from
observational and randomized studies previously
assessed in meta-analyses or systematic reviews [13,14].
The reason for including only studies previously included
in systematic reviews or meta-analyses was to increase the
likelihood that all articles on a given topic were reviewed.
Meta-analyses of fewer than four OSs were excluded from
our review, because they provided limited ability to eval-
uate influences of study design characteristics on results of
OSs.
Study characteristics abstracted
To determine characteristics that should be abstracted, we
reviewed the literature as to how RCTs should be reported
[15,16] and evaluated [17], how OSs should be reported
and evaluated [18], and how patient and treatment char-
acteristics influence RCTs [19]. Some information from
RCTs was not relevant for OSs (e.g., blinding of the rand-
omization process), some was relevant but not available
in OSs (e.g., protocols for administering the primary treat-
ment and managing intermediate outcomes), and some
was not relevant to comparing studies (e.g., power of the
study when data have already been collected).
Based on previous literature and our own experience with
OSs, we developed the schema in Table 1 for study char-
acteristics that could influence results by influencing
either the study's applicability or validity. Factors that
could influence applicability include specific characteris-
tics of the treatments, outcomes, or subjects; results that
apply to studies using specific types of treatments, out-
come measurements or subjects may be valid, but may
not be reproduced by other studies using different types of
treatments, outcome measurements or subjects.
Table 1: Study Characteristics That Influence Results
Characteristics That Influence Applicability
Treatment specifics
Details of procedure
Details of ancillary treatments or management of intermediate 
outcomes
Outcome
Definition
Method of patient contact and assessment at follow-up
Length of follow-up
Patient characteristics
Study setting
Inclusion/exclusion criteria
Reported characteristics
Characteristics That Influence Validity
Information bias
Incorrectly ascertaining treatment or outcome
Selection bias
Pretreatment – subjects on different treatments have different 
risks
Post treatment – lost to follow-up depends on outcome and 
treatment
Confounding
Caused by pretreatment selection bias
Demonstrated by differences in risk factors between treatment 
groups
Possibly reduced by risk-adjustmentEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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Factors that could influence validity include those that
could contribute to confounding, selection, or informa-
tion (also called measurement) bias [20]. Confounding
arises when subjects who receiving one treatment differ in
risk from subjects receiving another, independent of the
effect of treatment. Selection bias occurs when the associ-
ation between exposure and disease differs between those
who complete a study and those in the target population.
In cohort studies of medical treatments, such as those
reviewed below, pre-treatment selection bias leads to con-
founding and post-treatment selection bias results from
incomplete follow-up that differs according to both out-
come and treatment. Information bias occurs when errors
are made in assessing which treatment or outcome a
patient had. Although post-treatment selection bias and
information bias distort estimates of effect size, they were
difficult to assess in the papers reviewed and were not
recorded in our analysis.
This schema guided the type of information abstracted
from the reviewed articles. Although it does not include
all 27 items considered important for measuring the qual-
ity of OSs in one schema [18], it is conceptually simple
and should include most study aspects that influence
interpretation of results. For each article reviewed, we
noted critical data elements omitted from the article.
We deemed that the likelihood of confounding would be
increased if treatment choice were related to time, so that
recent patients generally received one treatment, whereas
patients from several years previously received another.
Confounding could also be more likely if treatment was
allocated on the basis of patient characteristics that con-
tribute to treatment failure, either by the physician or
through patient self-selection. Confounding was consid-
ered less likely if the physicians treating the patients used
only one procedure. An implicit assumption in this crite-
rion is that patient risk and quality of care are similar
across physicians; this assumption may not be valid in all
cases, but we wanted to judge the studies as generously as
possible so that reports of deficiencies in these studies
would be conservative. Another criterion for decreased
likelihood of confounding was an abrupt change in
patient care, so that all patients received one treatment
before the change and all patients received another treat-
ment after the change.
All data abstraction was from the original articles.
Although the majority of articles were assessed independ-
ently by two different reviewers, some articles were only
assessed by the same reviewer several months apart. Disa-
greements between reviewers, between reviews at different
times, or between our reviewers and the published meta-
analysis were resolved through discussion.
Statistical methods
Results were reported as statistically significant if p < 0.05,
although p-values were often much lower. We used a 2-
by-2 χ2-test for contingency tables to compare OS and
RCT subjects for pooled failure rates on the same treat-
ment. Significantly different failure rates for OS and RCT
studies of one treatment in a comparison but not the
other is a sensitive indication of possible confounding in
the OSs. Significantly different failure rates for both treat-
ments suggest that the two types of studies may differ with
respect to features that influence failure rates (e.g.,
patients, outcome measures, specifics of the treatment, or
uses of ancillary treatments). We also evaluated whether it
might be worthwhile to search for important study factors
that caused heterogeneity by examining variation among
OSs for failure rates of a given treatment. The p-value for
the statistical significance of this variation was determined
using a 2-by-k χ2-test for contingency tables, where k was
the number of studies that evaluated a given treatment.
Pearson's correlation coefficient, denoted r, was used to
compute the p-value for the association between the fail-
ure rates in the treatment group and the failure rates in the
control group at the 0.05 significance level.
Statistical methods were used to combine odds ratios
from several studies and to test the difference between the
summary odds ratios from the observational and
randomized studies. To combine odds ratios from several
studies and to find the standard error of the combined
odds ratio, we used a fixed-effects calculation [21]. By
using fixed- rather than random-effects calculations [22],
we obtained smaller standard errors and decreased the
chances of missing true differences. However, this method
may increase the likelihood of finding spurious
differences.
We tested the difference between two odds ratios using
the equation
Z = (Ln1 - Ln2) / √(SE1
2 + SE2
2)
where Z has a normal distribution with mean zero and
variance 1, Ln1 and Ln2 are the logarithms of the two odds
ratios, and SE1 and SE2 are the standard errors of these log-
arithms. Heterogeneity in odds ratios was tested with the
Breslow-Day test for homogeneity at the 0.05 significance
level.
Results
Meta-analyses selected for review
The selected analyses are shown in Table 2. These analyses
addressed 10 topics: anticoagulants for treatment of myo-
cardial infarction, quinidine for atrial fibrillation, trial of
labor for patients with a breech delivery, colposuspension
compared to anterior colporrhaphy for urinaryEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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incontinence, colposuspension compared to needle sus-
pension for urinary incontinence, transcutaneous electri-
cal nerve stimulation (TENS) for treatment of postsurgical
pain, early discharge following childbirth, hip screws for
hip fracture, local anesthesia for patients with carotid
endarterectomy, and hysterosalpingography (HSG)
media on pregnancy.
With five exceptions, we considered as observational all
studies that were considered observational in the reviewed
meta-analyses [13]: three of these were excluded because
they used alternately assigned controls [23-25], and two
were RCTs [26,27]. We did not exclude studies that used
historical controls. Seven additional studies that were not
in English were excluded because we were not able to
accurately abstract detailed information about them.
Some studies assessed more than one outcome. With one
exception, we reported results for the same outcomes that
were assessed in the study by Ioannidis et al [13]. The
exception was the meta-analysis of quinidine [28]. The
outcome used by Ioannidis et al. from that analysis was
mortality, which was zero or near zero for most studies.
We used relapse of atrial fibrillation following cardiover-
sion, which was used by our other source of meta-analyses
[14]. Failure rates were used to compute odds ratios not
computed by the original studies. For some studies the
success rates and odds ratios in the primary studies [29-
32] differed from those reported by Ioannidis et al. [13] or
the meta-analysis [28]. When there was a discrepancy, we
used the rates reported in the primary studies. Rates in pri-
mary studies for positive endpoints (e.g. pregnancy) were
converted to failure rates (e.g. no pregnancy).
Comparisons of observational and randomized studies
The comparison of the combined odds ratios for the two
types of studies are shown in Figure 1. In general, the con-
fidence intervals were wider for the RCTs than for the OSs,
reflecting the larger sample sizes for the OSs. Wide confi-
dence intervals for randomized controlled studies of trial
of labor, transcutaneous electrical nerve stimulation
(TENS), early discharge, and local anesthesia prevented
Table 2: Meta-analyses Selected for Review
Brief Title Year Medical Condition Treatment 1 v 
Treatment 2
Failure Outcome No. of studies 
(RCT, OS)
Reasons for excluding OSs 
previously compared to RCTs 
[13]
Anticoagulants 1977 Myocardial 
Infarction
Control v 
Anticoagulants
Mortality Ioannidis: (6, 12) 
Kunz: (6, 12)
Three used alternately assigned 
controls [23-25].
Quinidine 1992 Atrial fibrillation Control v 
Quinidine
Relapse into atrial 
fibrillation
Ioannidis: (6, 5) 
Kunz: (6, 6)
One did not have 3-month 
follow-up [53].
Trial of Labor 1995 Breech delivery No trial v Trial of 
Labor
5 minute Apgar Ioannidis: (2, 6) None excluded.
Colposuspension 1 1996 Incontinence Anterior 
colporrhaphy v 
Colposuspension
No cure of 
incontinence
Ioannidis: (4, 11) Five were in a foreign language 
[54-58].
Colposuspension 2 1996 Incontinence Needle suspension 
v Colposuspension
No cure of 
incontinence
Ioannidis: (3, 9) One used failed surgery instead 
of incontinence as an outcome 
[59]. One was a controlled trial 
[26]. Three were in a foreign 
language [55, 56, 60].
Transcutaneous 
Electrical Nerve 
Stimulation (TENS)
1996 Post-operative 
pain
Control v TENS No pain relief Ioannidis: (2, 4) 
Kunz: (17, 19)
None excluded.
Early Discharge 1997 Childbirth Conventional v 
Early
Maternal 
Morbidity
Ioannidis: (1, 3) Added one study from original 
meta-analysis [36].
Hip screw 1999 Hip fracture Fixed nail plates v 
Sliding hip screw
Total 
complications
Ioannidis: (1, 6) One "OS" was an RCT [27].
Local Anesthesia 1996 Carotid 
Endarterectomy
General v Local 
Anesthesia
Stroke or death Ioannidis: (3, 14) One from a non-peer reviewed 
abstract [61], 1 from 
unpublished data [62], one in a 
foreign language [63].
Hysterosalpingo-
graphy (HSG)
1999 Infertility Water v Oil in 
Hysterosalpingogr
aphy
No Pregnancy Ioannidis: (5, 6) None excluded.
RCT = Randomized Controlled Trial
OS = Observational StudyEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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Comparison of Confidence Intervals for Combined Odds Ratios from Observational Studies and Randomized Controlled  Trials Figure 1
Comparison of Confidence Intervals for Combined Odds Ratios from Observational Studies and Randomized Controlled 
Trials.
RCT= Randomized Controlled Trial
OS=Observational Study
TENS= Transcutaneous Electrical Nerve Stimulation
HSG= Hysterosalpingography
Anticoagulants
RCT .77 (.65, .92)
OS .35 (.30, .40)
Quindine
RCT .35 (.26, .47)
OS .54 (.36, .81)
Trial of Labor
RCT 1.7 (.33, 8.8)
OS 1.3 (.91, 2.0)
Colposuspension 1
RCT .29 (.15, .53)
OS .63 (.45, .83)
Colposuspension 2
RCT .31 (.17, .59)
OS .56 (.37, .83)
TENS
RCT .26 (.05, 1.2)
OS .47 (.27, .82)
Early Discharge
RCT .66 (.15, 2.9)
OS .87 (.59, 1.3)
Hip Screw
RCT .14 (.04, .5)
OS .16 (.11, .25)
Local Anesthesia
RCT 1.0 (.24, 4.2)
OS .46 (.30, .70)
HSG
RCT .53 (.38, .74)
OS .52 (.42, .64)
95% Confidence Intervals for Odds RatiosEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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meaningful comparisons for these treatment areas. The
only treatment area for which the odds ratios differed sig-
nificantly was studies of anticoagulants following an acute
myocardial infarction.
The observational and randomized studies differed with
respect to several failure rates (see Table 3). For some
treatment comparisons there were dissimilar failure rates
between the types of studies for both treatment and
control groups (TENS for postoperative pain and early dis-
charge following childbirth), and for other treatment
comparisons there were significant differences between
study designs with respect to the rates for patients with the
new treatments, but not for patients on the older treat-
ments (quinidine for the treatment of atrial fibrillation
and colposuspension versus two older treatments for uri-
nary incontinence).
Table 3: Outcome Differences Between RCTs and OSs
Brief Title (outcome) Number of Studies Average Failure Rate (Number of Patients)
Control** Treatment
Anticoagulants (MI) [13, 14, 64]
RCT 6 17% (1748) 14% (2106)
OS 9 31%† (3615) 16%† (2598)
Quinidine (Afib) [13, 14, 28] 3 months
RCT 6 54% (390) 36% (413)
OS 5 61%* (200) 53% (342)
Trial of labor (Breech) [13, 65]
RCT 2 2% (128) 3% (182)
OS 6 5% (1043) 4%† (1552)
Colposuspension 1 (Incontinence) [13, 66]
RCT 2 33% (134) 12% (139)
OS 6 37%† (508) 26% (374)
Colposuspension 2 (Incontinence) [13, 66]
RCT 2 31% (132) 12% (139)
OS 4 32%† (190) 23%† (349)
TENS (Pain) [13, 14, 67]
RCT 2 18% (34) 3% (34)
OS 4 76%† (172) 56%† (136)
Early Discharge (Childbirth) [13, 68]
RCT 1 8% (38) 5% (93)
OS 4 21%† (379) 19%† (402)
Hip Screw (Hip Fx) [13, 69]
RCT 1 50% (26) 12% (33)
OS 5 35%† (290) 8% (560)
Local Anesthesia (CEA) [11, 13, 70]
RCT 3 5% (79) 5% (75)
OS 11 5%* (1509) 2% (1713)
HSG (Infertility) [11, 13, 71]
RCT 5 81% (527) 69% (302)
OS 6 74%† (734) 58%† (1072)
RCT = Randomized Controlled Trial; OS = Observational Study
MI = Myocardial Infarction
Afib = Atrial fibrillation
TENS = Transcutaneous electrical nerve stimulation
Hip Fx = Hip Fracture
CEA = Carotid Endarterectomy
HSG = Hysterosalpingography
** The treatment group is listed in the row title. As seen in Table 1, the control (i.e. comparison) groups are the negative of the listed treatment 
except for the following: Control group for colposuspension 1 is colporrhaphy, colposuspension 2 is needle suspension, hip fracture is fixed nail 
plates, CEA is general anesthesia, infertility is water soluble medium.
Significance testing was only done to test heterogeneity among the failure rates for the observational studies
* P < .05 for test of heterogeneity of failure rates combined to create the average
† P < .001 for test of heterogeneity of failure rates combined to create the averageEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
Page 7 of 11
(page number not for citation purposes)
As indicated in Table 3, several studies show considerable
heterogeneity in results among OSs. For each treatment
comparison there was statistically significant variation in
failure rates for at least one of the treatments. There was
statistically significant heterogeneity in the odds ratios for
studies of anticoagulants, colporrhaphy, needle suspen-
sion, and hysterosalpingography. Despite small numbers
of studies in each treatment area, failure rates were signif-
icantly correlated for studies of anticoagulants (r = 0.79, p
= 0.01), trial of labor (r = 0.75, p = 0.08), early discharge
(r = 0.99, p = 0.01), hip screws (r = 0.93, p = 0.02), and
local anesthesia (r = 0.66, p = 0.03). This correlation
might be explained by substantial differences among
study features that influence failure rates.
Reporting of treatments and outcomes in OSs
Reporting details of the primary treatment, ancillary treat-
ments, and management of intermediate outcomes was
uniformly poor. Most aspects of outcome were also
poorly reported. However, outcome definitions were gen-
erally well reported. Even here there were exceptions: one
study of surgical treatment for incontinence defined the
subjective outcome only as "cured" [33], and another
defined it as "symptom free" [34].
Length of follow-up, which may substantially influence
outcome and comparisons of treatments, was usually not
well reported. Of the studies reviewed, only two studies of
hysterosalpingography and five of surgical treatment for
stress incontinence provided both the mean (or median)
and range (or other measure of spread) of follow-up
times. Eleven studies provided no follow-up information,
and the remainder provided only one number (median,
minimum, or undefined).
Considerations of patient selection in OSs
Even though the majority of studies were based on chart
abstraction, none described methods for reducing selec-
tion or information bias.
Results from studies were sometimes combined, even
though they differed with respect to potentially important
patient characteristics. For example, studies of surgical
treatment for incontinence varied with respect to exclu-
sions due to previous surgery for incontinence, detrussor
instability, and other pathologic findings. Another exam-
ple is that criteria for studies of local anesthesia for carotid
endarterectomy varied on the basis of whether patients
were included who were simultaneously undergoing a
coronary artery bypass grafting procedure or who had an
acute stroke. Among studies of early discharge, one
unique inclusion criteria was caesarian delivery [35] and
another was primiparity [36]. Of the two studies of HSG
that provided detail on inclusion and exclusion criteria,
one required infertility for at least two years [37] and a sec-
ond required infertility for only one year [38].
In Table 4 articles are rated for their reporting of patient
characteristics in a descriptive table. Articles were rated as
'A' if they reported at least one item in each of the catego-
ries of medical history, demographics, and clinical assess-
ment. Even with these minimal criteria a minority of
studies were categorized as 'A'; the only treatment areas
that had primarily 'A's were local anesthesia for carotid
endarterectomy and colporrhaphy or needle suspension
for incontinence. For one treatment area, early versus con-
ventional discharge, none of the OSs provided informa-
tion on maternal comorbidities or other relevant aspects
of medical history.
Factors that influence confounding
Table 4 also describes how study characteristics were
reported that could influence confounding. Confounding
was more likely in two studies because subjects on one
treatment were treated several years previously compared
with subjects on another. Confounding was also more
likely in other studies (the majority of trials of labor and
surgery for incontinence and half the studies of early dis-
charge [32,33]) because treatment was allocated on the
basis of patient characteristics likely to influence the pos-
sibility of treatment failure. Confounding may have been
less likely if the physicians treating the patients used only
one procedure. This occurred in a few studies of local
anesthesia for carotid endarterectomy, hip screws for hip
fracture, and contrast media for HSG. Confounding was
considered less likely in another study because of an
abrupt change in patient care [35]. In several studies it was
not possible to assess how patient preferences may have
influenced confounding [39-42].
Table 4 shows whether studies assessed the possibility of
confounding by comparing patients on the two treat-
ments with respect to at least one variable from the cate-
gories of medical history, demographics, and clinical
assessment. Most studies did not make these compari-
sons; the few that did should have evaluated additional
potential confounders. In addition, once potential
confounders were identified, the studies made only mini-
mal use of statistical methods to control for confounding.
A few studies attempted to control for confounding by
stratifying on the basis of some risk factors, but only one
study performed a regression analysis that adjusted for
multiple risk factors [43].
Reasons for OS heterogeneity
We found evidence that variation in outcome definition
and length of follow-up caused heterogeneity in results.
For example, in studies of trial of labor, the study with the
lowest failure rate [44] was also the study that definedEmerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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poor outcome in the newborn as a five-minute Apgar
score less than five, instead of less than seven as used in
other studies (the lower the score the more likely the new-
born is to require resuscitation). For studies of early dis-
charge, the lowest failure rate came from a study that
examined post-operative complications of C-section
patients, and the highest rates came from a study that
included many common symptoms in the definition of
maternal morbidity (e.g., cold, flu, and constipation). In
the studies comparing colposuspension to either needle
suspension or colporrhaphy, the lowest failure rates in the
colposuspension groups came from studies in which fol-
low-up was less than one-year, and those low failure rates
were very similar to the RCTs, both of which had follow-
up of one year. For the study of HSG with the lowest odds
ratio (0.98) [37], the duration of follow-up was two years,
as compared to the other studies which had follow-up of
one year or less. It is possible that infertility problems that
improved with oil-contrast media may have resolved in
any case over a two-year period.
Reasons for differences between observational and 
randomized studies
Differences for the studies of TENS for postoperative pain
and early discharge following childbirth may have been
due in part to dissimilar definitions of failure. The OSs of
TENS defined this as whether or not a patient received
post-operative medications. The randomized controlled
trials used verbal ratings of pain that were dichotomized
into "satisfactory" or "unsatisfactory". For studies of early
discharge, the randomized controlled trial defined failure
as maternal problems requiring physician referral. These
problems were primarily infections: urinary tract infec-
tions, episiotomy infection, mastitis, subinvolution, and
endometritis. Most OSs defined failure as maternal prob-
lems determined from physical assessment or self-report.
Since these problems included constipation, flu-like
Table 4: Reporting of Patient Characteristics and Efforts to Assess and Control Confounding
Quinidine 
(Afib) 
(n = 6)
Trial of Labor 
(Breech) 
(n = 6)
Colposuspension 1 
(Incontinence) 
(n = 6)
Colposuspension 2 
(Incontinence) 
(n = 4)
Early 
Discharge 
(Childbirth) 
(n = 4)
Hip Screw 
(Hip Fx) 
(n = 5)
Local 
Anesthesi
a (CEA) 
(n = 11)
HSG 
(Infertility) 
(n = 6)
Patient 
Characterization*
A = 4 A = 3 A = 5 A = 3 A = 0 A = 3 A = 7 A = 1
B = 2 B = 3 B = 1 B = 1 B = 3 B = 1 B = 4 B = 3
C = 0 C = 0 C = 0 C = 0 C = 1 C = 1 C = 0 C = 0
D = 0 D = 0 D = 0 D = 0 D = 0 D = 0 D = 0 D = 2
Treatment 
Selection
A = 0 A = 0 A = 0 A = 0 A = 1 A = 1 A = 5 A = 3
B = 0 B = 0 B = 0 B = 0 B = 1 B = 0 B = 3 B = 0
C = 0 C = 6 C = 5 C = 4 C = 2 C = 0 C = 1 C = 1
D = 6 D = 0 D = 1 D = 0 D = 0 D = 4 D = 2 D = 2
Comparison of risk 
factors*
A = 0 A = 2 A = 5 A = 3 A = 0 A = 1 A = 5 A = 1
B = 3 B = 3 B = 1 B = 0 B = 3 B = 2 B = 6 B = 2
C = 0 C = 1 C = 0 C = 0 C = 1 C = 0 C = 0 C = 0
D = 3 D = 0 D = 0 D = 1 D = 0 D = 2 D = 0 D = 3
Statistical 
Adjustment‡
A A = 0 A = 0 A = 0 A = 0 A = 1 A = 0 A = 1 A = 0
B B = 1 B = 3 B = 1 B = 2 B = 0 B = 2 B = 0 B = 0
C C = 5 C = 3 C = 5 C = 2 C = 3 C = 3 C = 10 C = 6
Afib = Atrial fibrillation
Hip Fx = Hip Fracture
CEA = Carotid Endarterectomy
HSG = Hysterosalpingography
* Characterizations or comparisons were given an 'A' if they included least one element in each of the following categories: demographics, medical 
history, and clinical assessment. They were given a 'B' if they included one medical history or clinical assessment variable, a 'C' if they included one 
demographic variable, and a 'D' if there were no characterization or comparisons.
 Treatment selection methods were given an 'A' if they probably reduced confounding, a 'B' if the effect on confounding was uncertain, a 'C' if 
confounding was probably increased, and a 'D' if they were not described.
† Statistical adjustment was given an 'A' for using multiple regression, 'B' for using stratification, and 'C' for no adjustment.Emerging Themes in Epidemiology 2005, 2:8 http://www.ete-online.com/content/2/1/8
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symptoms, and lethargy as well as infections, failure rates
were generally higher for observational than for rand-
omized studies. The one exception was an observational
study that examined outcomes post-caesarian section and
defined failure as fever, wound infection etc [35]. The fail-
ure rates for this study were 6% for early discharge and 7%
for the conventional group, which are similar to the rates
from randomized studies. Without this study of C-section
patients, the overall failure rates for the observational and
randomized studies would have differed even more.
The primary concern about OSs is confounding. There
was evidence of obvious confounding that was not taken
into account in three treatment comparisons: 1) influence
of anticoagulants on survival of myocardial infarction
(historical controls treated several years earlier [45-47]
and anticoagulants preferentially given to younger
patients and patients at lower risk for other reasons
[48,49]) 2) quinidine for the treatment of arrhythmias
(significantly higher [50,51] rates of valvular heart disease
in the quinidine group), and 3) colposuspension versus
anterior colporrhaphy (substantially and significantly
higher rates in the colposuspension group of severe pre-
surgery incontinence [52]). [32,34] In no study showing
obvious confounding did the authors assess or adjust for
confounding, or even raise it as a concern.
Discussion
Previous studies have compared results of OSs and RCTs.
The present investigation was the first to evaluate what
design features could have influenced results of OSs and,
therefore, the comparisons of results from OSs and RCTs.
We found evidence that some factors unrelated to validity
(treatment specifics, patient characteristics, and methods
of measuring outcomes) could have influenced results in
some of the studies. However, the comparisons of RCTs
and OSs (and in many cases the original meta-analyses
that combined the studies) did not take these study fea-
tures into account. Therefore, it is possible that some dif-
ferences between some RCTs and OSs may be due to
factors other than lack of validity of OSs.
Clearly, however, a critical validity issue (confounding)
influenced the results of some OSs. Patients on some
treatments differed substantially from patients on another
with respect to risk factors or ancillary treatments that
probably influenced outcomes and altered the observed
relative effectiveness of the two treatments. Unfortu-
nately, few studies assessed the possibility of confound-
ing, and almost none made a sophisticated effort to
control for it. Because of the potential for confounding to
invalidate the results of OSs, the lack of concern with con-
founding was surprising and disturbing.
The primary finding of this investigation was that few OSs
of medical treatments provided sufficient information for
their results to be adequately interpreted. The poor report-
ing impaired the ability of the systematic reviews and
meta-analyses that included these articles to explain dif-
ferences in results or decide how results should be com-
bined. It may also have contributed to our inability to
account for most of the variation in results among OSs
and the causes of discrepancies between OSs and RCTs.
Differences may have occurred because the OSs and RCTs
evaluated different treatments, defined outcomes differ-
ently, or had obvious confounding. The OSs reviewed did
not provide sufficient evidence to assess whether they
were invalid because of undetectable and unavoidable
confounding. This type of confounding is of greatest con-
cern in OSs and may have been responsible for differences
between OSs and RCTs of hormone replacement therapy.
Undetectable confounding may be less likely when
patients have little influence on treatment choice, such as
decisions about a specific surgical procedure.
In summary, our study provided little evidence either for
or against the validity of OSs. However, it suggested that
causes of differences previously found between OSs and
RCTs are difficult to determine. The OSs we examined
may not be representative of all OSs that evaluated medi-
cal treatments. However, the severe reporting problems in
the 61 studies reviewed suggest that many other published
studies provide inadequate information. Without
improved standards for reporting, it will be difficult to
assess how OSs on a given topic should be interpreted or,
more generally, the appropriate role for OSs in the evalu-
ation of medical treatments. Standards can be improved
by developing criteria for studies and involving more
researchers with a strong epidemiological background in
the design, reporting, and review of OSs of medical
treatments.
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